By 2050, antimicrobial infections are projected to cause 10 million deaths worldwide, outracing cancers. Therefore, new antimicrobial agents are urgently needed before the existing ones become ineffective.
Ynno Med developed an AI-assisted platform for discovering new drugs, specializing in the infectious disease area. They address the unmet clinical needs of new antimicrobial agents tackling antimicrobial resistance. As a university spin-off company, YnnoMed is commercializing the scientific and technological findings obtained from research activities to utilize the otherwise unexploited knowledge. As a drug R&D company, their goal is to design, develop, and distribute first-in-class antimicrobial medicines that can treat current antibiotic-resistant bacterial infections and suppress the generation of new antimicrobial resistance. Additionally, they can also provide drug design and discovery services, using their technology to facilitate industrial development.